[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 |
[2] |
YAMAOKA T, OHBA M, OHMORI T. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms[J]. Int J Mol Sci, 2017, 18(11):2420. doi: 10.3390/ijms18112420 |
[3] |
HANAWA M, SUZUKI S, DOBASHI Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus[J]. Int J Cancer, 2006, 118(5):1173-1180. doi: 10.1002/ijc.21454 |
[4] |
RUHSTALLER T, THUSS-PATIENCE P, HAYOZ S, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)[J]. Ann Oncol, 2018, 29(6):1386-1393. doi: 10.1093/annonc/mdy105 |
[5] |
HUANG Z H, MA X W, ZHANG J, et al. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials[J]. BMC Cancer, 2018, 18(1):1-13. doi: 10.1186/s12885-017-3892-2 |
[6] |
SUNTHARALINGAM M, WINTER K, ILSON D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer[J]. JAMA Oncol, 2017, 3(11):1520-1528. doi: 10.1001/jamaoncol.2017.1598 |
[7] |
LU M, WANG X C, SHEN L, et al. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: a single centre prospective phase Ⅱ trial[J]. Cancer Sci, 2016, 107(4):486-490. doi: 10.1111/cas.12894 |
[8] |
DUTTON S J, FERRY D R, BLAZEBY J M, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial[J]. Lancet Oncol, 2014, 15(8):894-904. doi: 10.1016/S1470-2045(14)70024-5 |
[9] |
XIE C, JING Z, LUO H, et al. Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial[J]. Br J Cancer, 2020, 123(11):1616-1624. doi: 10.1038/s41416-020-01054-6 |
[10] |
XU X L, LING Z Q, CHEN W, et al. The overexpression of VEGF in esophageal cancer is associated with a more advanced TMN stage: a meta-analysis[J]. Cancer Biomark, 2013, 13(2):105-113. doi: 10.3233/CBM-130343 |
[11] |
FUCHS C S, TOMASEK J, YONG C J, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5 |
[12] |
WILKE H, MURO K, VAN CUTSEM E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11):1224-1235. doi: 10.1016/S1470-2045(14)70420-6 |
[13] |
XU R H, ZHANG Y Q, PAN H M, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(12):1015-1024. doi: 10.1016/S2468-1253(21)00313-7 |
[14] |
LI Y W, FENG H, REN P, et al. Safety and efficacy of apatinib monotherapy for unresectable, metastatic esophageal cancer: a single-arm, open-label, phase Ⅱ study[J]. Oncologist, 2020, 25(10):e1464-e1472. doi: 10.1634/theoncologist.2020-0310 |
[15] |
CHU L, LIANG F, ZHANG J, et al. A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)[J]. Ann Oncol, 2019, 30:ix177. |
[16] |
ALMHANNA K, ROSA M, HENDERSON-JACKSON E, et al. Her-2 expression in gastroesophageal intestinal Metaplasia, dysplasia, and adenocarcinoma[J]. Appl Immunohistochem Mol Morphol, 2016, 24(9):633-638. doi: 10.1097/PAI.0000000000000243 |
[17] |
BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742):687-697. doi: 10.1016/S0140-6736(10)61121-X |
[18] |
DOI T, SHITARA K, NAITO Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study[J]. Lancet Oncol, 2017, 18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6 |
[19] |
MAKIYAMA A, SUKAWA Y, KASHIWADA T, et al. Randomized, phase Ⅱ study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study)[J]. J Clin Oncol, 2020, 38(17):1919-1927. doi: 10.1200/JCO.19.03077 |
[20] |
GUO X F, LI S S, ZHU X F, et al. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer[J]. Cancer Chemother Pharmacol, 2018, 82(3):383-394. doi: 10.1007/s00280-018-3627-3 |
[21] |
HECHT J R, BANG Y J, QIN S K, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: trio-013/LOGiC: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2016, 34(5):443-451. doi: 10.1200/JCO.2015.62.6598 |
[22] |
LYONS T G, KU G Y. Systemic therapy for esophagogastric cancer: targeted therapies[J]. Chin Clin Oncol, 2017, 6(5):48. doi: 10.21037/cco.2017.07.02 |
[23] |
SAHIN U, SCHULER M, RICHLY H, et al. A phase Ⅰ dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer[J]. Eur J Cancer, 2018, 100:17-26. doi: 10.1016/j.ejca.2018.05.007 |
[24] |
TÜRECI O, SAHIN U, SCHULZE-BERGKAMEN H, et al. A multicentre, phase Ⅱa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study[J]. Ann Oncol, 2019, 30(9):1487-1495. doi: 10.1093/annonc/mdz199 |
[25] |
SAHIN U, TÜRECI Ö, MANIKHAS G, et al. FAST: a randomised phase Ⅱ study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J]. Ann Oncol, 2021, 32(5):609-619. doi: 10.1016/j.annonc.2021.02.005 |
[26] |
LORDICK F, AL-BATRAN S E, GANGULI A, et al. Patient-reported outcomes from the phase Ⅱ FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma[J]. Gastric Cancer, 2021, 24(3):721-730. doi: 10.1007/s10120-020-01153-6 |
[27] |
CREEMERS A, EBBING E A, PELGRIM T C, et al. A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas[J]. Sci Rep, 2018, 8(1):13281. doi: 10.1038/s41598-018-31548-6 |
[28] |
IVESON T, DONEHOWER R C, DAVIDENKO I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study[J]. Lancet Oncol, 2014, 15(9):1007-1018. doi: 10.1016/S1470-2045(14)70023-3 |
[29] |
CATENACCI D V T, TEBBUTT N C, DAVIDENKO I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(11):1467-1482. doi: 10.1016/S1470-2045(17)30566-1 |
[30] |
CHUANG W Y, CHANG Y S, CHAO Y K, et al. Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma[J]. Int J Clin Exp Pathol, 2015, 8(10):12757-12765. |
[31] |
HIRASHIMA K, BABA Y, WATANABE M, et al. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2010, 17(9):2486-2493. doi: 10.1245/s10434-010-1040-1 |
[32] |
LI S J, WANG Z Q, HUANG J, et al. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis[J]. BMC Cancer, 2016, 16(1):1-17. doi: 10.1186/s12885-015-2026-y |
[33] |
ECKELMAN B P, SALVESEN G S, SCOTT F L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family[J]. EMBO Rep, 2006, 7(10):988-994. doi: 10.1038/sj.embor.7400795 |
[34] |
TU H L, COSTA M. XIAP’s profile in human cancer[J]. Biomolecules, 2020, 10(11):1493. doi: 10.3390/biom10111493 |
[35] |
PENG H, WANG L G, WANG X Z, et al. The correlation between XIAP gene polymorphisms and esophageal squamous cell carcinoma susceptibility and prognosis in a Chinese population[J]. Pathol Res Pract, 2017, 213(12):1482-1488. doi: 10.1016/j.prp.2017.10.008 |
[36] |
DIZDAR L, JÏ¿½NEMANN L, WERNER T, et al. Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer[J]. Oncol Lett, 2018, 15(3):3779-3789. |
[37] |
JIN Y X, LU X Y, WANG M D, et al. X-linked inhibitor of apoptosis protein accelerates migration by inducing epithelial-mesenchymal transition through TGF-β signaling pathway in esophageal cancer cells[J]. Cell Biosci, 2019, 9(1):76. doi: 10.1186/s13578-019-0338-3 |
[38] |
IWAI Y, ISHIDA M, TANAKA Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade[J]. Proc Natl Acad Sci USA, 2002, 99(19):12293-12297. doi: 10.1073/pnas.192461099 |
[39] |
DOI T, PIHA-PAUL S A, JALAL S I, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018, 36(1):61-67. doi: 10.1200/JCO.2017.74.9846 |
[40] |
SHAH M A, KOJIMA T, HOCHHAUSER D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus[J]. JAMA Oncol, 2019, 5(4):546-550. doi: 10.1001/jamaoncol.2018.5441 |
[41] |
JANJIGIAN Y Y, MARON S B, CHATILA W K, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(6):821-831. doi: 10.1016/S1470-2045(20)30169-8 |
[42] |
KELLY R J, AJANI J A, KUZDZAL J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13):1191-1203. doi: 10.1056/NEJMoa2032125 |
[43] |
DOKI Y, AJANI J A, KATO K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma[J]. N Engl J Med, 2022, 386(5):449-462. doi: 10.1056/NEJMoa2111380 |
[44] |
YANG W X, XING X B, YEUNG S C J, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(1):e003497. doi: 10.1136/jitc-2021-003497 |
[45] |
WAGENER-RYCZEK S, SCHOEMMEL M, KRAEMER M, et al. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma[J]. Cancer Immunol Immunother, 2020, 69(4):523-533. doi: 10.1007/s00262-019-02475-w |
[46] |
BANG Y J, CHO J Y, KIM Y H, et al. Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer[J]. Clin Cancer Res, 2017, 23(19):5671-5678. doi: 10.1158/1078-0432.CCR-17-0025 |
[47] |
RALPH C, ELKORD E, BURT D J, et al. Modulation of lymphocyte regulation for cancer therapy: a phase Ⅱ trial of tremelimumab in advanced gastric and esophageal adenocarcinoma[J]. Clin Cancer Res, 2010, 16(5):1662-1672. doi: 10.1158/1078-0432.CCR-09-2870 |